Adaptimmune Therapeutics Plc ADR [ADAP] stock is trading at $0.25, up 26.90%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling.
From an analyst’s perspective:
Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] stock has seen the most recent analyst activity on July 30, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $4. Previously, Scotiabank started tracking the stock with Sector Outperform rating on May 30, 2024, and set its price target to $3.15. On March 24, 2023, Bryan Garnier initiated with a Buy rating and assigned a price target of $3.60 on the stock. Guggenheim upgraded its rating to a Buy but stick to its price target of $5 on January 03, 2023. Mizuho upgraded its rating to a Buy but $9 remained the price target by the analyst firm on November 09, 2022. Barclays started tracking with a Underweight rating for this stock on May 28, 2021, and assigned it a price target of $4. In a note dated April 22, 2020, Mizuho initiated an Neutral rating and provided a target price of $3 on this stock.
Adaptimmune Therapeutics Plc ADR [ADAP] stock has fluctuated between $0.20 and $1.55 over the past year. Currently, Wall Street analysts expect the stock to reach $2.83 within the next 12 months. Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] shares were valued at $0.25 at the most recent close of the market. An investor can expect a potential return of 1032.0% based on the average ADAP price forecast.
Analyzing the ADAP fundamentals
Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP] reported sales of 178.56M for the trailing twelve months, which represents a growth of 1269.96%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -0.39%, Pretax Profit Margin comes in at -0.39%, and Net Profit Margin reading is -0.4%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -1.33 and Total Capital is -0.38. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of6.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.2122 points at the first support level, and at 0.1745 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.2706, and for the 2nd resistance point, it is at 0.2913.
Ratios To Look Out For
For context, Adaptimmune Therapeutics Plc ADR’s Current Ratio is 2.92. Further, the Quick Ratio stands at 2.80, while the Cash Ratio is 1.41. Considering the valuation of this stock, the price to sales ratio is 0.36, the price to book ratio is 5.40.
Transactions by insiders
Recent insider trading involved Norry Elliot, Chief Medical Officer, that happened on Jan 17 ’25 when 5584.0 shares were sold. Chief Patient Supply Officer, Lunger John completed a deal on Jan 17 ’25 to sell 5584.0 shares. Meanwhile, Chief Operating Officer Bertrand William C JR sold 5584.0 shares on Jan 17 ’25.
